uniQure N.V. - Ordinary Shares (QURE): Price and Financial Metrics
QURE Price/Volume Stats
| Current price | $4.67 | 52-week high | $22.48 |
| Prev. close | $4.71 | 52-week low | $4.61 |
| Day low | $4.61 | Volume | 547,800 |
| Day high | $4.75 | Avg. volume | 994,984 |
| 50-day MA | $5.37 | Dividend yield | N/A |
| 200-day MA | $6.92 | Market Cap | 223.40M |
QURE Stock Price Chart Interactive Chart >
uniQure N.V. - Ordinary Shares (QURE) Company Bio
uniQure is a biopharmaceutical company, developing adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company was founded in 1998 and is based in Amsterdam, the Netherlands.
Latest QURE News From Around the Web
Below are the latest news stories about UNIQURE NV that investors may wish to consider to help them evaluate QURE as an investment opportunity.
Investors still aren’t sold on UniQure’s gene therapy for Huntington’sThe biotechnology company’s share price fell more than 10% Tuesday after the disclosure of more data from a small study. |
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to an inclusion criteria-matched natural history of the disease ~ ~ Mean CSF NfL continue to demonstrate favorable trends with low-dose patients below baseline at 30 months and high-dose patients near baseline at 18 months ~ ~ AMT-130 continues to be generally well-tolerated across both doses ~ ~ Data support continuing clinical development of AMT- |
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia BGlobal biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) today announced the three-year results from the pivotal HOPE-B study confirming continued long-term durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb) following a one-time infusion in people living with hemophilia B. The data showing that a one-time infusion of HEMGENIX offers elevated and sustained factor IX activity levels for years were presented in an oral presentation at the 65th American Society of Hematology (ASH) A |
12 Best Genomics Stocks To Buy NowIn this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now. If there’s one thing that can be said with certainty […] |
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)LEXINGTON, Mass. and AMSTERDAM, Dec. 08, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the grant of inducement equity awards to newly hired employees. The company granted equity awards to 28 employees as a material inducement to commencing their employment. In the aggregate, those employees received 142,300 restricted share units and options to purchase 52,500 ordinar |
QURE Price Returns
| 1-mo | -10.02% |
| 3-mo | -15.86% |
| 6-mo | -22.17% |
| 1-year | -76.39% |
| 3-year | -85.58% |
| 5-year | -91.15% |
| YTD | -31.02% |
| 2023 | -70.14% |
| 2022 | 9.31% |
| 2021 | -42.60% |
| 2020 | -49.58% |
| 2019 | 148.65% |
Continue Researching QURE
Want to see what other sources are saying about uniQure NV's financials and stock price? Try the links below:uniQure NV (QURE) Stock Price | Nasdaq
uniQure NV (QURE) Stock Quote, History and News - Yahoo Finance
uniQure NV (QURE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...